drugset / Trial / NCT07585383
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This study aims to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsules in healthy subjects. This study will be conducted in China. It will enroll male and female participants aged 18 years to 45 years.
Timeline
- Start
- 2026-05-19
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KR23248 | Unknown | 0.5 mg | Oral |
| Subject | KR23248 | Unknown | 1 mg | Oral |
| Subject | KR23248 | Unknown | 2 mg | Oral |
| Subject | KR23248 | Unknown | 3 mg | Oral |
| Subject | KR23248 | Unknown | 4.5 mg | Oral |
| Subject | KR23248 | Unknown | 6 mg | Oral |